Bio-Techne (TECH) Common Equity (2009 - 2026)

Bio-Techne's Common Equity history runs 18 years deep, the most recent figure standing at $2.1 billion for Q1 2026.

• In Q1 2026, Common Equity rose 3.33% year-over-year to $2.1 billion; the TTM figure through Mar 2026 stood at $2.1 billion (up 3.33% YoY), while the FY2025 annual figure was $1.9 billion, down 7.25% from the prior year.
• Common Equity for Q1 2026 stood at $2.1 billion, up from $2.0 billion in the prior quarter.
• The five-year high for Common Equity was $2.1 billion in Q3 2024, with the low at $1.7 billion in Q2 2022.
• The 5-year median for Common Equity is $2.0 billion (2023), against an average of $1.9 billion.
• The sharpest annual moves came in 2023 and 2025: Common Equity advanced 15.61% in 2023, then declined 8.08% in 2025.
• Bio-Techne's Common Equity stood at $1.8 billion in 2022, then climbed by 7.47% to $2.0 billion in 2023, then rose by 5.85% to $2.1 billion in 2024, then dropped by 3.25% to $2.0 billion in 2025, then rose by 3.7% to $2.1 billion in 2026.
• Business Quant data shows TECH's Common Equity at $2.1 billion in Q1 2026, $2.0 billion in Q4 2025, and $2.0 billion in Q3 2025.